Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: Results from two randomized clinical trials of bupropion

Addiction

Volumn 108, Issue 12, 2013, Pages 2202-2211

  David, Sean P ^a,b,c   Strong, David R ^d   Leventhal, Adam M ^e   Lancaster, Molly A ^e   Mcgeary, John E ^f   Munafò, Marcus R ^g   Bergen, Andrew W ^b   Swan, Gary E ^b   Benowitz, Neal L ^h   Tyndale, Rachel F ⁱ   Conti, David V ^e   Brown, Richard A ^c   Lerman, Caryn ^j   Niaura, Raymond ^c,k  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SRI INTERNATIONAL   (United States)

^c BROWN UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g UNIVERSITY OF BRISTOL   (United Kingdom)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

Bupropion; First lapse; Genetic; Pharmacogenetic analysis; Randomized clinical trial

Indexed keywords

AMFEBUTAMONE; ANKK1 PROTEIN, HUMAN; CATECHOL METHYLTRANSFERASE; COMT PROTEIN, HUMAN; DOPAMINE; DOPAMINE 4 RECEPTOR; DOPAMINE TRANSPORTER; DOPAMINE UPTAKE INHIBITOR; DRD4 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SLC6A3 PROTEIN, HUMAN;

CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PREVENTION AND CONTROL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SMOKING; SMOKING CESSATION; TANDEM REPEAT; ARTICLE; CONTROLLED CLINICAL TRIAL; FIRST LAPSE; GENETIC; METHODOLOGY; PHARMACOGENETIC ANALYSIS; RANDOMIZED CLINICAL TRIAL;

BUPROPION; CATECHOL O-METHYLTRANSFERASE; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, DOPAMINE D4; SMOKING; SMOKING CESSATION; TANDEM REPEAT SEQUENCES;

BUPROPION; FIRST LAPSE; GENETIC; PHARMACOGENETIC ANALYSIS; RANDOMIZED CLINICAL TRIAL;

EID: 84887607716     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12325     Document Type: Article

References (63)

1. Jha P., Ramasundarahettige C., Landsman V., Rostron B., Thun M., Anderson R. N. etal. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med 2013; 368: 341-350.
2. Hughes J. R., Stead L. F., Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007 Jan 24; (1): CD000031.
3. Cahill K., Stead L. F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012; (4): CD006103.
4. Stead L. F., Perera R., Bullen C., Mant D., Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012; (11): CD000146.
5. Stead L. F., Lancaster T. Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev 2012; (12): CD009670.
6. Carmelli D., Swan G. E., Robinette D., Fabsitz R. Genetic influence on smoking-a study of male twins. N Engl J Med 1992; 327: 829-833.
7. Heath A. C., Martin N. G., Lynskey M. T., Todorov A. A., Madden P. A. Estimating two-stage models for genetic influences on alcohol, tobacco or drug use initiation and dependence vulnerability in twin and family data. Twin Res 2002; 5: 113-124.
8. Li M. D., Cheng R., Ma J. Z., Swan G. E. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction 2003; 98: 23-31.
9. Broms U., Silventoinen K., Madden P. A., Heath A. C., Kaprio J. Genetic architecture of smoking behavior: a study of Finnish adult twins. Twin Res Hum Genet 2006; 9: 64-72.
10. True W. R., Heath A. C., Scherrer J. F., Waterman B., Goldberg J., Lin N. etal. Genetic and environmental contributions to smoking. Addiction 1997; 92: 1277-1287.
11. McCaffery J. M., Papandonatos G. D., Lyons M. J., Koenen K. C., Tsuang M. T., Niaura R. Educational attainment, smoking initiation and lifetime nicotine dependence among male Vietnam-era twins. Psychol Med 2008; 38: 1287-1297.
12. Gold A. B., Lerman C. Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. Hum Genet 2012; 131: 857-876.
13. David S. P., Munafò M. R. Genetic variation in the dopamine pathway and smoking cessation. Pharmacogenomics 2008; 9: 1307-1321.
14. King D. P., Paciga S., Pickering E., Benowitz N. L., Bierut L. J., Conti D. V. etal. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology 2011; 37: 641-650.
15. Kortmann G. L., Dobler C. J., Bizarro L., Bau C. H. Pharmacogenetics of smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet 2009; 153B: 17-28.
16. Ray R., Tyndale R. F., Lerman C. Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet 2009; 23: 252-261.
17. Fryer J. D., Lukas R. J. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 1999; 288: 88-92.
18. Ascher J. A., Cole J. O., Colin J. N., Feighner J. P., Ferris R. M., Fibiger H. C. etal. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56: 395-401.
19. Faucette S. R., Hawke R. L., Lecluyse E. L., Shord S. S., Yan B., Laethem R. M. etal. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 2000; 28: 1222-1230.
20. Zhu A. Z., Cox L. S., Nollen N., Faseru B., Okuyemi K. S., Ahluwalia J. S. etal. CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion. Clin Pharmacol Ther 2012; 92: 771-777.
21. Kortmann G. L., Dobler C. J., Bizarro L., Bau C. H. Pharmacogenetics of smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 17-28.
22. Lotsch J., Fluhr K., Neddermayer T., Doehring A., Geisslinger G. The consequence of concomitantly present functional genetic variants for the identification of functional genotype-phenotype associations in pain. Clin Pharmacol Ther 2009; 85: 25-30.
23. McGeary J. E., Knopik V. S., Hayes J. E., Palmer R. H., Monti P. M., Kalman D. Predictors of relapse in a bupropion trial for smoking cessation in recently-abstinent alcoholics: preliminary results using an aggregate genetic risk score. Subst Abuse 2012; 6: 107-114.
24. Wang J., Li M. D. Common and unique biological pathways associated with smoking initiation/progression, nicotine dependence, and smoking cessation. Neuropsychopharmacology 2010; 35: 702-719.
25. Culbertson C. S., Bramen J., Cohen M. S., London E. D., Olmstead R. E., Gan J. J. etal. Effect of bupropion treatment on brain activation induced by cigarette-related cues in smokers. Arch Gen Psychiatry 2011; 68: 505-515.
26. Nikolova Y. S., Ferrell R. E., Manuck S. B., Hariri A. R. Multilocus genetic profile for dopamine signaling predicts ventral striatum reactivity. Neuropsychopharmacology 2011; 36: 1940-1947.
27. Stice E., Yokum S., Burger K., Epstein L., Smolen A. Multilocus genetic composite reflecting dopamine signaling capacity predicts reward circuitry responsivity. J Neurosci 2012; 32: 10093-10100.
28. Uhl G. R., Drgon T., Johnson C., Walther D., David S. P., Aveyard P. etal. Genome-wide association for smoking cessation success: participants in the Patch in Practice trial of nicotine replacement. Pharmacogenomics 2010; 11: 357-367.
29. Uhl G. R., Liu Q. R., Drgon T., Johnson C., Walther D., Rose J. E. etal. Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry 2008; 65: 683-693.
30. Uhl G. R., Drgon T., Johnson C., Ramoni M. F., Behm F. M., Rose J. E. etal. Genome wide association for smoking cessation success in a trial of precessation nicotine replacement. Mol Med 2010; 16: 513-526.
31. Uhl G. R., Walther D., Musci R., Fisher C., Anthony J. C., Storr C. L. etal. Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances. Mol Psychiatry 2012. doi: 10.1038/mp.2012.155. [Epub ahead of print].
32. Drgon T., Johnson C., Walther D., Albino A. P., Rose J. E., Uhl G. R. etal. Genome-wide association for smoking cessation success: participants in a trial with adjunctive denicotinized cigarettes. Mol Med 2009; 15: 268-274.
33. Hughes J. R., Keely J. P., Niaura R. S., Ossip-Klein D. J., Richmond R. L., Swan G. E. etal. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res 2003; 5: 13-25.
34. Brown R. A., Niaura R., Lloyd-Richardson E. E., Strong D. R., Kahler C. W., Abrantes A. M. etal. Bupropion and cognitive-behavioral treatment for depression in smoking cessation. Nicotine Tob Res 2007; 9: 721-730.
35. David S. P., Brown R. A., Papandonatos G. D., Kahler C. W., Lloyd-Richardson E. E., Munafò M. R. etal. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res 2007; 9: 821-833.
36. Lerman C., Shields P. G., Wileyto E. P., Audrain J., Pinto A., Hawk L. etal. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 2002; 12: 627-634.
37. David S. P., Strong D. R., Munafò M. R., Brown R. A., Lloyd-Richardson E. E., Evins E. A. etal. Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob Res 2007; 9: 1251-1257.
38. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association; 1994.
39. Heatherton T. F., Kozlowski L. T., Frecker R. C., Fagerstrom K. O. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991; 86: 1119-1127.
40. Conti D. V., Lee W., Li D., Liu J., Van Den Berg D., Thomas P. D. etal. Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum Mol Genet 2008; 17: 2834-2848.
41. Lerman C., Shields P. G., Wileyto E. P., Audrain J., Hawk L. H., Pinto A. etal. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 2003; 22: 541-548.
42. Leventhal A. M., David S. P., Brightman M., Strong D., McGeary J. E., Brown R. A. etal. Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation. Pharmacogenomics J 2012; 12: 86-92.
43. Bergen A. W., Javitz H. S., Su L., He Y., Conti D. V., Benowitz N. L. etal. The DRD4 exon III VNTR, bupropion, and associations with prospective abstinence. Nicotine Tob Res 2012; 15: 1190-1200.
44. David S. P., Johnstone E., Griffiths S. E., Murphy M., Yudkin P., Mant D. etal. No association between functional catechol-O-methyl transferase 1947A>G polymorphism and smoking initiation, persistent smoking or smoking cessation. Pharmacogenetics 2002; 12: 265-268.
45. Berrettini W. H., Wileyto E. P., Epstein L., Restine S., Hawk L., Shields P. etal. Catechol-Omethyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol Psychiatry 2007; 61: 111-118.
46. Vandenbergh D. J., Rodriguez L. A., Hivert E., Schiller J. H., Villareal G., Pugh E. W. etal. Long forms of the dopamine receptor (DRD4) gene VNTR are more prevalent in substance abusers: no interaction with functional alleles of the catechol-O-methyltransferase (COMT) gene. Am J Med Genet 2000; 96: 678-683.
47. George S. R., Cheng R., Nguyen T., Israel Y., O'Dowd B. F. Polymorphisms of the D4 dopamine receptor alleles in chronic alcoholism. Biochem Biophys Res Commun 1993; 196: 107-114.
48. Strong D. R., Therneau T. coxme: Mixed Effects Cox Models. R package version 2.2-3. 2012. URL: http://cran.r-project.org/web/packages/coxme/ [accessed on 5 September 2013].
49. Strong D. R., Harrell F. E. Regression Modeling Strategies. R package version 3.6-2. 2012. URL: http://www.r-project.org/ [accessed on 5 September 2013].
50. Strong D. R., Bates D., Maechler M., Bolker B. lme4: Linear mixed-effects models using S4 classes. R package. 2012. URL: http://cran.r-project.org/web/packages/lme4/ [accessed on 5 September 2013].
51. Powell J., Dawkins L., West R., Pickering A. Relapse to smoking during unaided cessation: clinical, cognitive and motivational predictors. Psychopharmacology (Berl) 2010; 212: 537-549.
52. Strong D. R., Kahler C. W., Leventhal A. M., Abrantes A. M., Lloyd-Richardson E., Niaura R. etal. Impact of bupropion and cognitive-behavioral treatment for depression on positive affect, negative affect, and urges to smoke during cessation treatment. Nicotine Tob Res 2009; 11: 1142-1153.
53. Chen L. S., Baker T. B., Piper M. E., Breslau N., Cannon D. S., Doheny K. F. etal. Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. Am J Psychiatry 2012; 169: 735-742.
54. Bergen A. W., Javitz H. S., Krasnow R., Nishita D., Michel M., Conti D. V. etal. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenet Genomics 2013; 23: 94-103.
55. Businelle M. S., Kendzor D. E., Reitzel L. R., Costello T. J., Cofta-Woerpel L., Li Y. etal. Mechanisms linking socioeconomic status to smoking cessation: a structural equation modeling approach. Health Psychol 2010; 29: 262-273.
56. Shiffman S., Scharf D. M., Shadel W. G., Gwaltney C. J., Dang Ql, Paton S. M. etal. Analyzing milestones in smoking cessation: illustration in a nicotine patch trial in adult smokers. J Consult Clin Psychol 2006; 74: 276-285.
57. Leventhal A. M., Japuntich S. J., Piper M. E., Jorenby D. E., Schlam T. R., Baker T. B. Isolating the role of psychological dysfunction in smoking cessation: relations of personality and psychopathology to attaining cessation milestones. Psychol Addict Behav 2012; 26: 838-849.
58. Japuntich S. J., Leventhal A. M., Piper M. E., Bolt D. M., Roberts L. J., Fiore M. C. etal. Smoker characteristics and smoking-cessation milestones. AmJPrev Med 2011; 40: 286-294.
59. Japuntich S. J., Piper M. E., Leventhal A. M., Bolt D. M., Baker T. B. The effect of five smoking cessation pharmacotherapies on smoking cessation milestones. J Consult Clin Psychol 2011; 79: 34-42.
60. Manolio T. A., Collins F. S., Cox N. J., Goldstein D. B., Hindorff L. A., Hunter D. J. etal. Finding the missing heritability of complex diseases. Nature 2009; 461: 747-753.
61. Sarginson J. E., Killen J. D., Lazzeroni L. C., Fortmann S. P., Ryan H. S., Schatzberg A. F. etal. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet 2011; 156B: 275-284.
62. Dahl J. P., Jepson C., Levenson R., Wileyto E. P., Patterson F., Berrettini W. H. etal. Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence. Pharmacogenomics J 2006; 6: 194-199.
63. Gold A. B., Wileyto E. P., Lori A., Conti D., Cubells J. F., Lerman C. Pharmacogenetic association of the galanin receptor (GALR1) SNP rs2717162 with smoking cessation. Neuropsychopharmacology 2012; 37: 1683-1688.